Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsChungsoo Kim, PharmD, PhD
Assistant Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Assistant Professor Adjunct
Positions outside Yale
Assistant Professor (tenure), Biomedical Informatics, Ajou University School of Medicine
Biography
Prof. Chungsoo Kim is an Assistant Professor Adjunct in the Section of Cardiovascular Medicine and the Yale/YNHH Center for Outcomes Research and Evaluation (CORE). His primary position is a tenure-track Assistant Professor in the Department of Biomedical Informatics at Ajou University.
Prof. Kim received his PharmD from Ajou University College of Pharmacy and earned his PhD in Biomedical Informatics from the Department of Biomedical Sciences at the Graduate School of Medicine at the same university.
Prof. Kim's research interests focus on using real-world data to collaboratively build a healthier world. First, he aims to generate reliable evaluations and evidence regarding the effectiveness and safety of medications based on various data sources (EHR, claims, registries, etc.) and formats (OMOP, etc.) of real-world data. Second, he intends to apply AI and digital health methodologies to clinical practices and medication evaluations.
Last Updated on July 16, 2026.
Departments & Organizations
Education & Training
- Postdoctoral Associate
- Center for Outcomes Research (CORE) (2026)
- PhD
- Ajou University Graduate School of Medicine, Department of Biomedical Sciences (Major in Biomedical Informatics) (2024)
- PharmD
- Ajou University College of Pharmacy, Department of Pharmacy (Major in Pharmacy) (2019)
Research
Copy Link
Overview
Medical Research Interests
Cardiovascular Diseases; Comparative Effectiveness Research; Comparative Study; Data Science; Decision Making, Computer-Assisted; Decision Support Techniques; Drug Therapy; Medical Informatics; Multicenter Study
Public Health Interests
Bioinformatics; Cardiovascular Diseases; Chronic Diseases; Pharmaceuticals and Medical Devices; Regulatory Affairs; Survival Analysis; Health Informatics; Pharmacoepidemiology
ORCID
0000-0003-1802-1777
Research at a Glance
Yale Co-Authors
Frequent collaborators of Chungsoo Kim's published research.
Publications Timeline
A big-picture view of Chungsoo Kim's research output by year.
Research Interests
Research topics Chungsoo Kim is interested in exploring.
Harlan Krumholz, MD, SM
Yuan Lu, ScD
Rohan Khera, MD, MS
Yuntian Liu, MPH
Erica Spatz, MD, MHS
Hua Xu, PhD
61Publications
587Citations
Cardiovascular Diseases
Publications
2026
Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study
Kim C, Kim S, Lee D, Han E, Lee Y, You S. Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study. Diabetes Obesity And Metabolism 2026, 28: 8482-8493. PMID: 42380063, PMCID: PMC13448862, DOI: 10.1111/dom.70985.Peer-Reviewed Original ResearchAltmetricData Resource Profile: Health Insurance Review and Assessment Service Korean nationwide claims OMOP CDM (2015–24) database, HIRA K-OMOP
Yu D, Lim S, Shin H, Kim M, You S, Park R, Kim C. Data Resource Profile: Health Insurance Review and Assessment Service Korean nationwide claims OMOP CDM (2015–24) database, HIRA K-OMOP. International Journal Of Epidemiology 2026, 55: dyag131. PMID: 42501369, DOI: 10.1093/ije/dyag131.Peer-Reviewed Original ResearchTarget trial emulation of survival outcomes for clinically localized prostate cancer treatments
An M, Kim C, Min K, Yi K, Park R, Jung M. Target trial emulation of survival outcomes for clinically localized prostate cancer treatments. Discover Oncology 2026 PMID: 42286375, DOI: 10.1007/s12672-026-05392-4.Peer-Reviewed Original ResearchSingle-Pill Combination Therapy for Hypertension Persistent Underuse in the United States, 2015-2025
Choi K, Kim C, Spatz E, Krumholz H, Lu Y. Single-Pill Combination Therapy for Hypertension Persistent Underuse in the United States, 2015-2025. Journal Of The American College Of Cardiology 2026, 88: 360-363. PMID: 42089854, DOI: 10.1016/j.jacc.2026.03.088.Peer-Reviewed Original ResearchAltmetricComparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus
Bu F, Wu R, Ostropolets A, Aminorroaya A, Chen H, Chai Y, Dhingra L, Falconer T, Hsu J, Kim C, Lau W, Man K, Minty E, Morales D, Nishimura A, Thangraraj P, Van Zandt M, Yin C, Khera R, Hripcsak G, Suchard M. Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus. Journal Of The American College Of Cardiology 2026, 87: 2963-2977. PMID: 41984016, PMCID: PMC13191718, DOI: 10.1016/j.jacc.2026.02.5123.Peer-Reviewed Original ResearchCitationsAltmetricConceptssodium-glucose cotransporter 2 inhibitorsglucagon-like peptide 1 receptor agonistspeptide 1 receptor agonistscomparative effectiveness assessmentcompare cardiovascular effectscardiovascular diseaseGLP-1RAcardiovascular effectselectronic health record databasesodium-glucoserandom-effects meta-analysisGLP-1RAshealth record databasecardiovascular benefitscardiovascular disease subgroupsCox proportional hazards modelsEstablished cardiovascular diseasesecondary subgroup analysissecond-line therapyeffects of glucagon-like peptide 1 receptor agonistsmeta-analytic estimatesproportional hazards modeltype 2 diabetes mellituscardiovascular outcome trialspropensity score adjustmentReal-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetes
Kim C, Bu F, Blacketer C, Ostropolets A, Duarte-Salles T, Viernes B, Falconer T, Pistillo A, Li J, Yin C, Van Zandt M, Nagy P, Nishimura A, Minty E, You S, Sawano M, Sawano S, Jeon J, Aminorroaya A, Dhingra L, Pedroso A, Thangaraj P, Dorr D, Pratt N, Man K, Lau W, Morales D, Khera R, Schuemie M, Ryan P, Hripcsak G, Krumholz H, Suchard M, Lu Y. Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetes. Nature Communications 2026, 17: 7195. PMID: 41935054, PMCID: PMC13396638, DOI: 10.1038/s41467-026-71307-0.Peer-Reviewed Original ResearchAltmetricConceptsGLP-1 receptor agonistsreceptor agonistsantihyperglycemic agentsGLP-1SGLT2 inhibitorsclinical trialscomparative safetyrisk of diabetic ketoacidosishigh riskhigher risk of diabetic ketoacidosisrisk of peripheral edemamultinational cohort studyrisk of hypoglycemiaDPP-4 inhibitorspropensity score adjustmenttype 2 diabetesperipheral edemadiabetic ketoacidosisadverse eventscohort studyhazard ratioDPP-4safety outcomesagonistsreal-world evidenceGLP-1 Receptor Agonist Prescriptions for Adolescents With Obesity and Associated Disparities
Kim C, Sharifi M, Ross J, Chen Y, Xu H, Krumholz H, Lu Y. GLP-1 Receptor Agonist Prescriptions for Adolescents With Obesity and Associated Disparities. JAMA Pediatrics 2026, 180: 334-336. PMID: 41557442, PMCID: PMC12820773, DOI: 10.1001/jamapediatrics.2025.5708.Peer-Reviewed Original ResearchCitationsAltmetric
2025
Clustering of patients with severe asthma based on long-term percentage of forced expiratory volume in 1 second (FEV1) changes Real-world evidence
Lee Y, Chang J, Kim C, Lee E, Jang J, Park R, Park H. Clustering of patients with severe asthma based on long-term percentage of forced expiratory volume in 1 second (FEV1) changes Real-world evidence. Annals Of Allergy Asthma & Immunology 2025, 136: 538-544.e2. PMID: 41354271, DOI: 10.1016/j.anai.2025.12.002.Peer-Reviewed Original ResearchAltmetricSemaglutide and Tirzepatide Prescribing for Obesity in Patients With Preexisting Comorbid Cancers
Kim C, Dinan M, Robinson T, Ross J, Jastreboff A, Krumholz H, Lu Y. Semaglutide and Tirzepatide Prescribing for Obesity in Patients With Preexisting Comorbid Cancers. JAMA Oncology 2025, 12: 101-104. PMID: 41196576, PMCID: PMC12593664, DOI: 10.1001/jamaoncol.2025.4560.Peer-Reviewed Original ResearchCitationsAltmetricChanges in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide
Lu Y, Liu Y, Totojani T, Kim C, Khera R, Xu H, Brush J, Krumholz H, Abaluck J. Changes in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide. JAMA Network Open 2025, 8: e2526013. PMID: 40779264, PMCID: PMC12334959, DOI: 10.1001/jamanetworkopen.2025.26013.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptshealth care expenditurescardiovascular risk factorscare expenditurescohort studyrisk factorsYale New Haven Health Systemcohort study of adultstype 2 diabetes statuslong-term impactstudy of adultshealth systemretrospective cohort studyblood pressurehemoglobin A1c reductionMain Outcomestotal cholesterolSentara Healthcareinpatient staySecondary outcomesglucagon-like peptide-1 receptor agonistsprimary outcomehealthpeptide-1 receptor agonistsassociated with clinical outcomesassociated with reductions
News
Copy Link
Get In Touch
Copy Link